Prikaz osnovnih podataka o dokumentu

dc.creatorBrzaković, B. B.
dc.creatorVezmar-Kovačević, Sandra
dc.creatorVučićević, Katarina
dc.creatorMiljković, Branislava
dc.creatorMartinović, Žarko J.
dc.creatorPokrajac, Milena
dc.creatorProstran, Milica
dc.date.accessioned2019-09-02T11:27:19Z
dc.date.available2019-09-02T11:27:19Z
dc.date.issued2012
dc.identifier.issn0269-4727
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1634
dc.description.abstractWhat is known and Objective: Lamotrigine metabolism may be substantially altered with concomitant administration of valproic acid and/or carbamazepine. Such alterations may require the adjustment of lamotrigine dose to ensure optimal treatment efficacy and safety. Methods: The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy. Lamotrigine plasma steady-state oral clearance (CLss/F) and area under the curve (AUCss) were calculated from the dose of drug, average steady-state concentration (Css) and interval of administration. Multiple regression analysis was used for the identification and quantification of factors that influenced lamotrigine pharmacokinetics. Results and Discussion: Age and dose of carbamazepine and valproic acid had significant influence on lamotrigine CLss/F and AUCss. Carbamazepine was associated with a dose-dependent increase and valproic acid with a dose-dependent decrease of lamotrigine metabolism rate. The effect of carbamazepine was more pronounced. Younger patients were expected to metabolize lamotrigine more rapidly whereas overweight patients may be less susceptible to interactions. Gender had no influence on lamotrigine pharmacokinetics. What is new and Conclusion: The efficacy and safety of lamotrigine may be altered by concomitant administration of carbamazepine and valproic acid. The models developed may be useful for estimating doses of lamotrigine for individual patients to minimize clinically significant interactions. Therapeutic monitoring is advisable when those drugs are used concomitantly.en
dc.publisherWiley-Blackwell, Hoboken
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175023/RS//
dc.rightsrestrictedAccess
dc.sourceJournal of Clinical Pharmacy and Therapeutics
dc.subjectageen
dc.subjectcarbamazepineen
dc.subjectepilepsyen
dc.subjectinteractionsen
dc.subjectlamotrigineen
dc.subjectvalproic aciden
dc.titleImpact of age, weight and concomitant treatment on lamotrigine pharmacokineticsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractМиљковић, Бранислава; Вучићевић, Катарина; Везмар-Ковачевић, Сандра; Мартиновић, Жарко Ј.; Покрајац, Милена; Простран, Милица; Брзаковић, Б. Б.;
dc.citation.volume37
dc.citation.issue6
dc.citation.spage693
dc.citation.epage697
dc.citation.other37(6): 693-697
dc.citation.rankM22
dc.identifier.wos000310601200014
dc.identifier.doi10.1111/j.1365-2710.2012.01351.x
dc.identifier.pmid22583007
dc.identifier.scopus2-s2.0-84868343874
dc.type.versionpublishedVersion


Dokumenti

Thumbnail

Ovaj dokument se pojavljuje u sledećim kolekcijama

Prikaz osnovnih podataka o dokumentu